AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias and to provide temporary pain relief to thoracic surgery patients via ablation of peripheral nerves; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; and Estech cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

AtriCure Inc

AtriCure, Inc. engages in the provision of innovative products, professional education, and support for the treatment of atrial fibrillation. Its product, Isolator Synergy Ablation System, is a surgical device that treats the persistent longstanding persistent forms of atrial fibrillation in patients undergoing certain open concomitant procedures. Its cryoICE cryosurgery product offers a variety of cryoablation devices for use in multiple different types of cardiothoracic surgery. Its AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart's left atrial appendage. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.

Should you buy, sell, or hold AtriCure Inc (ATRC) ?

AtriCure Inc (ATRC) : Buy or Sell